{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:53:03Z","timestamp":1778626383719,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Farco-Pharma GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Neurogenic detrusor overactivity (NDO), caused by spinal cord injury or multiple sclerosis, is marked by involuntary bladder contractions and reduced urine volume. Current therapy requires frequent catheterization with oxybutynin hydrochloride. This work investigates a novel in situ forming implant (ISFI) with PLGA as a sustained-release formulation for the urinary bladder by quantifying drug release, polymer degradation, and solvent release in vitro. Methods\/Results: Various formulation parameters were investigated, of which the drug load and PLGA termination were found to have the highest impact on drug release and polymer degradation. An increase in drug load from 1.5% to 7.5% for implants with the ester-terminated PLGA enhanced the degradation from 0% to around 20% after 7 d. Oxybutynin base catalyzed the polymer degradation, as implants with PLGA 502 and 15% drug load exhibited a degradation of 33% compared to 0% for 1.5% drug load. In the case of 1.5% drug load, the degradation could be increased by the use of an acid-terminated PLGA, compared to an ester-terminated. Conclusion: In summary, the feasibility of a biodegradable ISFI for NDO patients was shown, which could allow a single administration up to approx. one week, improving the quality of life for NDO patients. Additionally, this work provided insight to which formulation parameters can help to parallel drug release and polymer degradation.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111369","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:47:36Z","timestamp":1761266856000},"page":"1369","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release"],"prefix":"10.3390","volume":"17","author":[{"given":"Michael Uwe","family":"Hartig","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany"},{"name":"Farco Pharma GmbH, 50670 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Appelhaus","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Vollenbr\u00f6ker","sequence":"additional","affiliation":[{"name":"Farco Pharma GmbH, 50670 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alf","family":"Lamprecht","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","article-title":"In situ forming implants\u2014An attractive formulation principle for parenteral depot formulations","volume":"161","author":"Kempe","year":"2012","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1016\/j.apsb.2024.07.003","article-title":"Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/acs.molpharmaceut.2c00945","article-title":"Paudel, Influence of plga end groups on the release profile of dexamethasone from ocular implants","volume":"20","author":"Saraf","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2019.03.016","article-title":"Polymer degradation induced drug precipitation in plga implants\u2014Why less is sometimes more","volume":"139","author":"Zlomke","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2019.12.044","article-title":"Fundamental insights in plga degradation from thin film studies","volume":"319","author":"Machatschek","year":"2020","journal-title":"J. Control Release"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2012.10.015","article-title":"Mathematical modeling of drug delivery from autocatalytically degradable plga microspheres\u2014A review","volume":"165","author":"Pack","year":"2013","journal-title":"J. Control Release"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"124121","DOI":"10.1016\/j.ijpharm.2024.124121","article-title":"In-situ forming plga implants: Towards less toxic solvents","volume":"657","author":"Ramos","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.xphs.2024.10.019","article-title":"Evaluation of the impact of the polymer end groups and molecular weight on in vitro and in vivo performances of plga based in situ forming implants for ketoprofen","volume":"114","author":"Saha","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.05.049","article-title":"The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems\u2014A review","volume":"415","author":"Fredenberg","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhang, X., Yang, L., Zhang, C., Liu, D., Meng, S., Zhang, W., and Meng, S. (2019). Effect of polymer permeability and solvent removal rate on in situ forming implants: Drug burst release and microstructure. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11100520"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17905","DOI":"10.1038\/s41598-022-22765-1","article-title":"Efficacy, according to urodynamics, of onabotulinumtoxina compared with antimus-carinic drugs, for neurogenic detrusor overactivity: A systematic review and network meta-analysis","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.14740\/jocmr3752","article-title":"Long-term efficacy, safety, and tolerability of modified intravesical oxybutynin chloride for neurogenic bladder in children","volume":"11","author":"Honda","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_13","first-page":"582","article-title":"Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial","volume":"35","author":"Albrecht","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"ref_14","first-page":"100100","article-title":"Intravesical drug delivery approaches for improved therapy of urinary bladder diseases","volume":"3","author":"Palugan","year":"2021","journal-title":"Int. J. Pharm. X"},{"key":"ref_15","first-page":"286","article-title":"Development of tar-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","volume":"43","author":"Daneshmand","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.farmac.2005.06.001","article-title":"High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products","volume":"60","year":"2005","journal-title":"Il Farm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","article-title":"Plga in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release","volume":"172","author":"Parent","year":"2013","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bakhrushina, E., Sakharova, P., Konogorova, P., Pyzhov, V., Kosenkova, S., Bardakov, A., Zubareva, I., and Krasnyuk, I. (2024). Burst release from in situ forming plga-based implants: 12 effectors and ways of correction. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010115"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12247-020-09480-y","article-title":"Optimization and in vitro evaluation of injectable sustained-release of levothyroxine using plga-peg-plga","volume":"16","author":"Kamali","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1081\/DDC-100102155","article-title":"Rheological characterization of hydroxypropylcellulose gels","volume":"25","author":"Ramachandran","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-019-12141-5","article-title":"Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery","volume":"10","author":"Benhabbour","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijpharm.2018.07.013","article-title":"In-situ forming plga implants for intraocular dexamethasone delivery","volume":"548","author":"Bode","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.7150\/thno.4181","article-title":"Noninvasive characterization of the effect of varying plga molecular weight blends on in situ forming implant behavior using ultrasound imaging","volume":"2","author":"Solorio","year":"2012","journal-title":"Theranostics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101556","DOI":"10.1016\/j.progpolymsci.2022.101556","article-title":"The influence of the functional end groups on the properties of polylactide-based materials","volume":"130","author":"Kost","year":"2022","journal-title":"Prog. Polym. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1039\/D1MA00600B","article-title":"Formulation of plga nano-carriers: Specialized modification for cancer therapeutic applications","volume":"3","author":"Chatterjee","year":"2022","journal-title":"Mater. Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105156","DOI":"10.1016\/j.jddst.2023.105156","article-title":"Electrospun nanofibers: Exploring process parameters, polymer selection, and recent applications in pharmaceuticals and drug delivery","volume":"90","author":"Abdulhussain","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejps.2008.03.004","article-title":"Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles","volume":"34","author":"Kranz","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2006.08.016","article-title":"Drugs acting as plasticizers in polymeric systems: A quantitative treatment","volume":"115","author":"Siepmann","year":"2006","journal-title":"J. Control Release"},{"key":"ref_29","first-page":"154239","article-title":"Enhanced degradation of lactide-co-glycolide polymer with basic nucleophilic drugs","volume":"2015","author":"Faraj","year":"2015","journal-title":"Adv. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.actbio.2017.09.033","article-title":"A pro-angiogenic degradable mg-poly(lactic-co-glycolic acid) implant combined with rhbfgf in a rat limb ischemia model","volume":"64","author":"Bao","year":"2017","journal-title":"Acta Biomater."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Joiner, J., Prasher, A., Young, I., Kim, J., Shrivastava, R., Maturavongsadit, P., and Benhabbour, R. (2022). Effects of drug physicochemical properties on in-situ forming implant polymer degradation and drug release kinetics. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061188"},{"key":"ref_32","unstructured":"(2025, April 23). DrugBank, Oxybutynin (db01062). Available online: https:\/\/go.drugbank.com\/drugs\/DB01062."},{"key":"ref_33","first-page":"315","article-title":"Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer","volume":"31","author":"Liu","year":"2024","journal-title":"Bioact. Mater."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1369\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:56:37Z","timestamp":1761267397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111369"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111369","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}